Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003934 · ClinicalTrials.gov registry record · Phase 3
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 420
- Enrollment target
NCT00003934: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00003934 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 420 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003934, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 420 participants
- Enrollment target
Study Summary
This randomized phase III trial is studying tretinoin and combination chemotherapy to see how well they work compared to tretinoin, combination chemotherapy, and arsenic trioxide in treating patients with acute promyelocytic leukemia that has not been treated previously. Drugs used in chemotherapy, such as daunorubicin, cytarabine, mercaptopurine, methotrexate, and arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Tretinoin may help leukemia cells develop into normal white blood cells. It is not yet known which regimen is more effective for acute promyelocytic leukemia.
Interventions
- DRUG mercaptopurine
- DRUG methotrexate
- DRUG cytarabine
- DRUG tretinoin
- DRUG daunorubicin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 1999-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003934
The ClinicalTrials.gov registry entry for NCT00003934 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mercaptopurine is the first listed.
NCT00003934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003934 about?
NCT00003934 is a clinical study titled "Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia". This randomized phase III trial is studying tretinoin and combination chemotherapy to see how well they work compared to tretinoin, combination chemotherapy, and arsenic trioxide in treating patients with acute promyelocytic leukemia that has not been treated previously. Drugs used in chemotherapy, ...
What is the current status of trial NCT00003934?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 420 participants. The study started on 1999-06.
What interventions are being tested in trial NCT00003934?
The interventions under investigation include: mercaptopurine (DRUG), methotrexate (DRUG), cytarabine (DRUG), tretinoin (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003934?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.